Moderna Shares Surge 130% After Breakthrough Personalized Skin Cancer Vaccine Trial

Moderna's stock soared over 130% in early trading on Wall Street following a major medical breakthrough announced on August 26. The company, together with pharmaceutical giant Merck, reported impressive results from a late-stage clinical trial involving more than 1,100 patients with melanoma, a serious form of skin cancer. The trial was halted early after the combined treatment significantly reduced cancer recurrence and metastasis compared to existing therapies.

The innovative treatment merges Merck's successful drug Keytruda with Moderna's mRNA-based personalized vaccine technology. Unlike traditional vaccines, this immunotherapy uses Neoantigen technology to tailor the vaccine to each patient's specific tumor by training the immune system to target unique cancer proteins, minimizing damage to healthy tissue.

This Phase 3 trial success is a critical milestone before regulatory approval and opens a new multi-hundred-billion-dollar oncology market for both companies. For Moderna, which has faced declining revenues and operational losses post-COVID vaccine demand, this offers a promising new growth engine. For Merck, the breakthrough helps counter the looming "patent cliff" for Keytruda expected in 2028 by enabling new patents and extending the drug's commercial life.

The achievement not only boosts investor confidence but also paves the way for expanding personalized cancer vaccines to other cancers like lung and kidney. This marks a significant advancement in cancer treatment and a new chapter in immunotherapy.

Summary: Moderna and Merck announced a successful Phase 3 trial of a personalized mRNA vaccine combined with Keytruda for melanoma, causing Moderna's stock to jump over 130%. The treatment significantly reduces cancer recurrence and opens a large new market for both companies.

Points: - Moderna shares jump over 130% after positive Phase 3 melanoma vaccine trial. - Trial combined Merck's Keytruda with Moderna's personalized mRNA vaccine. - Treatment significantly lowers melanoma recurrence and metastasis. - Phase 3 success precedes regulatory approval and market launch. - New therapy offers Moderna a post-COVID growth opportunity. - Merck extends Keytruda's patent life amid looming patent expiration. - Personalized vaccine approach may expand to other cancers.

Topic: health israel_relevant: false entities: {"people":[],"organizations":["Moderna","Merck"],"places":[]}